King's College London

Research portal

Translational Considerations in Nanomedicine: The Oncology Perspective

Research output: Contribution to journalReview articlepeer-review

Alberto Gabizon, Rafael T. M. de Rosales, Ninh M. La-Beck

Original languageEnglish
Pages (from-to)140-157
Number of pages18
JournalADVANCED DRUG DELIVERY REVIEWS
Volume158
DOIs
Accepted/In press9 Jun 2020
Published2020

Documents

King's Authors

Abstract

Nanoparticles can provide effective control of the release rate and tissue distribution of their drug payload, leading to major pharmacokinetic and pharmacodynamic changes vis-à-vis the conventional administration of free drugs. In the last two decades, we have witnessed major progress in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in the approval for clinical use of several products and in new and promising approaches. Despite these advances, clinical applications of nanoparticle-based therapeutic and imaging agents remain limited due to biological, immunological, and translational barriers. There is a need to make high impact advances toward translation. In this review, we address biological, toxicological, immunological, and translational aspects of nanomedicine and discuss approaches to move the field forward productively. Overcoming these barriers may dramatically improve the development potential and role of nanomedicines in the oncology field and help meet the high expectations.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454